DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: Abatacept
Drug: Prednisone

First Posted Date: 2005-07-14

Last Posted Date: 2014-09-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 183

Registration Number: NCT00119678

Locations: 🇺🇸
8737 Beverly Blvd., Los Angeles, California, United States
🇺🇸
Office Of Geoffrey S. Dolan, Md, Long Beach, California, United States
🇺🇸
Kentuckiana Center For Better Bone And Joint Health, Louisville, Kentucky, United States

and more 10 locations

DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

Not Applicable

Completed

Conditions: HIV Infections
AIDS

First Posted Date: 2005-06-30

Last Posted Date: 2011-04-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 65

Registration Number: NCT00116415

Locations: 🇺🇸
Local Institution, Dallas, Texas, United States

Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)

Phase 3

Completed

Conditions: HIV Infections
AIDS

First Posted Date: 2005-06-29

Last Posted Date: 2011-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 900

Registration Number: NCT00116298

Locations: 🇹🇭
Local Institution, Nontaburi, Thailand

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

Phase 4

Completed

Conditions: HIV Infections
AIDS

First Posted Date: 2005-06-28

Last Posted Date: 2011-04-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT00116116

Locations: 🇺🇸
Local Institution, Dallas, Texas, United States

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Phase 3

Completed

Conditions: Renal Transplantation

Interventions: Drug: Cyclosporin A
Drug: Belatacept More Intensive Regimen (MI)
Drug: Belatacept Less Intensive Regimen (LI)

First Posted Date: 2005-06-20

Last Posted Date: 2017-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 595

Registration Number: NCT00114777

Locations: 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸
University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
National Institute Of Transplantation, Los Angeles, California, United States

and more 26 locations

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

Not Applicable

Completed

Conditions: Sepsis
Nosocomial Infections
Staphylococcal Infections
Candidemia

First Posted Date: 2005-06-07

Last Posted Date: 2012-08-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2000

Registration Number: NCT00113191

MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2005-06-03

Last Posted Date: 2021-09-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 27

Registration Number: NCT00112580

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
NCI - Surgery Branch, Bethesda, Maryland, United States

Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

Phase 4

Completed

Conditions: Metabolic Syndrome
Hypertension

Interventions: Drug: Irbesartan
Drug: Hydrochlorothiazide

First Posted Date: 2005-05-10

Last Posted Date: 2011-04-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 400

Registration Number: NCT00110422

Locations: 🇪🇸
Local Institution, Zaragoza, Spain

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

First Posted Date: 2005-04-01

Last Posted Date: 2010-09-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1440

Registration Number: NCT00106808

Locations: 🇺🇦
Local Institution, Simferopol, Ukraine

Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

First Posted Date: 2005-02-24

Last Posted Date: 2008-09-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 53

Registration Number: NCT00104130

Locations: 🇺🇸
Georgia Cancer Specialists, Tucker, Georgia, United States
🇺🇸
Kaiser Permanente NW Oncology Clinic, Portland, Oregon, United States
🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy